Fig. 5
Comparative performance analysis confirms robust predictive ability of pathCHEMO. a, b Comparison of pathCHEMO (turquoise) to other commonly utilized methods, including Panja et al. Epi2GenR (yellow), Zhong et al. SVM (light blue), Yu et al. PRES random forest (dark blue) using (a) ROC analysis (with AUROC indicated) and (b) Kaplan–Meier and Cox proportional hazards model (with log-rank p-value and hazard ratio indicated) in Tang et al. validation cohort. c Multivariable Cox proportional hazards analysis demonstrating adjustment of seven candidate pathways for common covariates (i.e., age, gender and stage at diagnosis). Hazard p-value is indicated. d Multivariable Cox proportional hazards analysis demonstrating adjustment of seven candidate pathways for signatures of lung cancer aggressiveness, including Larsen et al. (54 lung adenocarcinoma markers), Beer et al. (50 lung adenocarcinoma markers), and Tang et al. (12 non-small cell lung cancer markers). Hazard p-value is indicated
